chloroquine has been researched along with Long QT Syndrome in 24 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In fact, two of the actually used drugs against SARS-CoV2, such as chloroquine and the combination lopinavir/ritonavir, might determine a QT (the time from the start of the Q wave to the end of the T wave) interval prolongation and they show several interactions with antiarrhythmic drugs and antipsychotic medications, making them prone to an increased risk of developing arrhythmias." | 5.12 | COVID-19 and the burning issue of drug interaction: never forget the ECG. ( Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S, 2021) |
| "Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment." | 3.96 | Concentration-dependent mortality of chloroquine in overdose. ( Baud, FJ; Clemessy, JL; Hoglund, RM; Megarbane, B; Tarning, J; Watson, JA; White, NJ, 2020) |
| " The choice of (typically subtherapeutic) dosing regimens, influenced partly by "QT-phobia," varied widely and seems anecdotal without any pharmacologically reliable supporting clinical evidence." | 2.72 | Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. ( Shah, RR, 2021) |
| " Food and Drug Administration's Adverse Event Reporting System (FAERS) (>13 million total reports) were used." | 1.62 | Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. ( Brown, JD; Cicali, B; Henriksen, CH; Sarayani, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 21 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chotsiri, P | 1 |
| Tarning, J | 2 |
| Hoglund, RM | 2 |
| Watson, JA | 2 |
| White, NJ | 2 |
| Sarayani, A | 1 |
| Cicali, B | 1 |
| Henriksen, CH | 1 |
| Brown, JD | 1 |
| Javelot, H | 1 |
| El-Hage, W | 1 |
| Meyer, G | 1 |
| Becker, G | 1 |
| Michel, B | 1 |
| Hingray, C | 1 |
| Monzani, A | 1 |
| Genoni, G | 1 |
| Scopinaro, A | 1 |
| Pistis, G | 1 |
| Kozel, D | 1 |
| Secco, GG | 1 |
| Asensio, E | 1 |
| Acunzo, R | 1 |
| Uribe, W | 1 |
| Saad, EB | 1 |
| Sáenz, LC | 1 |
| Yahya, AS | 1 |
| Khawaja, S | 1 |
| Chukwuma, J | 1 |
| Weehuizen, JM | 1 |
| Hoepelman, AIM | 1 |
| Sun, J | 1 |
| Chen, Y | 1 |
| Fan, X | 1 |
| Wang, X | 2 |
| Han, Q | 1 |
| Liu, Z | 1 |
| Baud, FJ | 1 |
| Megarbane, B | 1 |
| Clemessy, JL | 1 |
| Hsia, BC | 1 |
| Greige, N | 1 |
| Quiroz, JA | 1 |
| Khokhar, AS | 1 |
| Daily, J | 1 |
| Di Biase, L | 1 |
| Ferrick, KJ | 1 |
| Fisher, JD | 1 |
| Krumerman, A | 1 |
| Sciaccaluga, C | 1 |
| Cameli, M | 1 |
| Menci, D | 1 |
| Mandoli, GE | 1 |
| Sisti, N | 1 |
| Cameli, P | 1 |
| Franchi, F | 1 |
| Mondillo, S | 1 |
| Valente, S | 1 |
| Danjuma, MI | 1 |
| Sinha, U | 1 |
| Fatima, H | 1 |
| Mohamed, MFH | 1 |
| Nathoe, H | 1 |
| Zekarias, A | 1 |
| Watson, S | 1 |
| Vidlin, SH | 1 |
| Grundmark, B | 1 |
| Shah, RR | 1 |
| Alkasir, A | 1 |
| Lippmann, S | 1 |
| Zequn, Z | 1 |
| Yujia, W | 1 |
| Dingding, Q | 1 |
| Jiangfang, L | 1 |
| Becker, ML | 1 |
| Snijders, D | 1 |
| van Gemeren, CW | 1 |
| Kingma, HJ | 1 |
| van Lelyveld, SFL | 1 |
| Giezen, TJ | 1 |
| Brüggemann, RJ | 1 |
| Moes, DJAR | 1 |
| van Rhee, KP | 1 |
| van 't Veer, NE | 1 |
| Koch, BCP | 1 |
| van Rossum, M | 1 |
| Windsant-van den Tweel, AV | 1 |
| Reijers, MHE | 1 |
| van Kimmenade, RRJ | 1 |
| Rahamat-Langedoen, JC | 1 |
| Rettig, TCD | 1 |
| van Raalte, R | 1 |
| van Paassen, J | 1 |
| Polderman, FN | 1 |
| van der Linden, PD | 1 |
| Frenzel, T | 1 |
| de Mast, Q | 1 |
| Burger, DM | 1 |
| Schouten, J | 1 |
| van de Veerdonk, FL | 1 |
| Pickkers, P | 1 |
| Ter Heine, R | 1 |
| Ehrlich, H | 1 |
| Elkbuli, A | 1 |
| Diaz-Arocutipa, C | 1 |
| Brañez-Condorena, A | 1 |
| Hernandez, AV | 1 |
| Ding, J | 1 |
| Liu, W | 1 |
| Guan, H | 1 |
| Feng, Y | 1 |
| Bao, Y | 1 |
| Li, H | 1 |
| Zhou, Z | 1 |
| Chen, Z | 1 |
| Yelve, K | 1 |
| Phatak, S | 1 |
| Patil, MA | 1 |
| Pazare, AR | 1 |
| Stas, P | 1 |
| Faes, D | 1 |
| Noyens, P | 1 |
| Mansfield, RJ | 1 |
| Thomas, RD | 1 |
6 reviews available for chloroquine and Long QT Syndrome
| Article | Year |
|---|---|
Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
Topics: Adult; Aged; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; | 2020 |
Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 229E, H | 2020 |
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral | 2021 |
Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dose-Response Relati | 2021 |
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; ERG1 Potassium Chan | 2021 |
QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Long QT Sy | 2021 |
1 trial available for chloroquine and Long QT Syndrome
| Article | Year |
|---|---|
An open-label cluster-randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC)-Protocol publication.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
17 other studies available for chloroquine and Long QT Syndrome
| Article | Year |
|---|---|
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.
Topics: Adult; Antimalarials; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; DN | 2022 |
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Interactions; D | 2021 |
COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
Topics: Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Hydr | 2020 |
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Chloroquine; Coronavirus Infec | 2020 |
The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
Topics: Adrenal Cortex Hormones; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hyd | 2020 |
Concentration-dependent mortality of chloroquine in overdose.
Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
Topics: Age Distribution; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Coronavirus Inf | 2020 |
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.
Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; | 2020 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agent | 2020 |
COVID-19 and Cardiac Concerns for Psychiatric Patients.
Topics: Antidepressive Agents; Antiviral Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular | 2020 |
QTc Prolongation in COVID-19 Patients Using Chloroquine.
Topics: Aged; Chloroquine; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Female; H | 2021 |
Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals.
Topics: Aged; Chloroquine; COVID-19 Drug Treatment; Electrocardiography; Female; Humans; Long QT Syndrome; M | 2021 |
Cardiac arrhythmias in COVID-19 patients: A combination of viral comorbidities and pro-arrhythmic drug interactions.
Topics: Angiotensin-Converting Enzyme 2; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithro | 2021 |
Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; D | 2021 |
Syncope in a patient being treated for hepatic and intestinal amoebiasis.
Topics: Amebicides; Antiprotozoal Agents; Chloroquine; Dysentery, Amebic; Furans; Humans; Hypokalemia; Liver | 2012 |
Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine.
Topics: Adult; Antimalarials; Chloroquine; Defibrillators, Implantable; Echocardiography; Electrocardiograph | 2008 |
Recurrent syncope. Drug induced long QT syndrome.
Topics: Adult; Anti-Allergic Agents; Antimalarials; Astemizole; Chloroquine; Electrocardiography; Humans; Lo | 2001 |